中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 9
Sep.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(9): 2091-2098

Effect of micro-ribonucleic acid-21 on the malignant biological behavior of cholangiocarcinoma cells by targeting the PTEN/PI3K/Akt pathway

DOI: 10.3969/j.issn.1001-5256.2022.09.026
  • a.

    Department of General Surgery, The Affiliated Hospital of Hebei University of Engineering, Handan, Hebei 056000, China

  • b.

    Department of Gynecology, The Affiliated Hospital of Hebei University of Engineering, Handan, Hebei 056000, China

Research funding:

Scientific Research Plan Project of Hebei Provincial Administration of Traditional Chinese Medicine (2020227)

More Information
  • Corresponding author: ZHOU Liyuan, zhouliyuan0310@126.com (ORCID: 0000-0002-6540-0369)
  • Received Date: 2022-01-14
  • Accepted Date: 2022-02-18
  • Published Date: 2022-09-20
    Abstract
  •   Objective  To investigate the effect of micro-ribonucleic acid-21(miR-21) on the malignant biological behavior of human cholangiocarcinoma cell line QBC939 by targeting the protein tyrosine phosphatase (PTEN)/inositol phosphate 3-kinase (PI3K)/protein kinase B (Akt) pathway.  Methods  The cholangiocarcinoma cell line QBC939 in the logarithmic growth phase was divided into empty vector group, blank control group, overexpression group, and silencing group.An inverted fluorescence microscope was used to observe transfection efficiency; MTT assay, flow cytometry, Transwell assay, and wound healing assay were used to measure cell proliferative activity, apoptosis rate, invasion activity, and migration activity.Quantitative reverse transcription PCR was used to measure the mRNA expression levels of miR-21, PTEN, PI3K, Akt, and mammalian target of rapamycin (mTOR); Western blotting was used to measure the protein expression levels of PTEN, PI3K, Akt, phosphorylated Akt (p-Akt), and mTOR; dual-luciferase reporter assay was used to verify the effect of miR-21 on PTEN.A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the SNK-q test was used for further comparison between two groups.  Results  Transfection efficiency was 90.27%±18.03% in the overexpression group, 91.43%±18.26% in the silencing group, and 92.16%±18.41% in the empty vector group.Compared with the blank control group and the empty vector group, the overexpression group had a significant increase in the proliferative activity of QBC939 cells (both P < 0.05) and a significant reduction in apoptosis rate (both P < 0.01);compared with the blank control group, the empty vector group, and the overexpression group, the silencing group had a significant reduction in proliferative activity (P < 0.01) and a significant increase in apoptosis rate (P < 0.01).Compared with the blank control group and the empty vector group, the overexpression group had significant increases in the migration rate of QBC939 cells and number of cells penetrating the membrane (all P < 0.01);compared with the blank control group, the empty vector group, and the overexpression group, the silencing group had significant reductions in migration rate and number of cells penetrating the membrane (all P < 0.01).Compared with the blank control group and the empty vector group, the overexpression group had significant increases in the mRNA expression levels of miR-21, PI3K, Akt, and mTOR and a significant reduction in the mRNA expression level of PTEN (all P < 0.05);compared with the blank control group, the empty vector group, and the overexpression group, the silencing group had significant reductions in the mRNA expression levels of miR-21, PI3K, Akt, and mTOR and a significant increase in the mRNA expression level of PTEN (all P < 0.05).Compared with the blank control group and the empty vector group, the overexpression group had significant increases in the protein expression levels of PI3K, Akt, p-Akt, and mTOR and a significant reduction in the protein expression level of PTEN (all P < 0.01);compared with the blank control group, the empty vector group, and the overexpression group, the silencing group had significant reductions in the protein expression levels of PI3K, Akt, p-Akt, and mTOR and a significant increase in the protein expression level of PTEN (all P < 0.01).Furthermore, miR-21 showed targeted regulation of PTEN expression.  Conclusion  MiR-21 silencing may inhibit the malignant biological behavior of human cholangiocarcinoma cell line QBC939 by targeting the PTEN/PI3K/Akt signaling pathway to upregulate the expression of PTEN and downregulate the expression of PI3K, Akt, mTOR, and p-Akt.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    CARPINO G, CARDINALE V, FOLSERAAS T, et al. Neoplastic transformation of the peribiliary stem cell niche in cholangiocarcinoma arisen in primary sclerosing cholangitis[J]. Hepatology, 2019, 69(2): 622-638. DOI: 10.1002/hep.30210.
    [2]
    KHAN SA, TAVOLARI S, BRANDI G. Cholangiocarcinoma: Epidemiology and risk factors[J]. Liver Int, 2019, 39(Suppl 1): 19-31. DOI: 10.1111/liv.14095.
    [3]
    WANG M, CHEN Z, GUO P, et al. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential[J]. J Cell Mol Med, 2021, 25(2): 618-628. DOI: 10.1111/jcmm.16151.
    [4]
    CILLO U, FONDEVILA C, DONADON M, et al. Surgery for cholangiocarcinoma[J]. Liver Int, 2019, 39 (Suppl 1): 143-155. DOI: 10.1111/liv.14089.
    [5]
    KONTOMANOLIS EN, KOUTRAS A, SYLLAIOS A, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: A review[J]. Anticancer Res, 2020, 40(11): 6009-6015. DOI: 10.21873/anticanres.14622.
    [6]
    CARNEIRO BA, EL-DEIRY WS. Targeting apoptosis in cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17(7): 395-417. DOI: 10.1038/s41571-020-0341-y.
    [7]
    JIANG N, DAI Q, SU X, et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior[J]. Mol Biol Rep, 2020, 47(6): 4587-4629. DOI: 10.1007/s11033-020-05435-1.
    [8]
    ZHU B, WEI Y. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway[J]. Cancer Med, 2020, 9(2): 783-796. DOI: 10.1002/cam4.2719.
    [9]
    CHEN L, YANG ZS, ZHOU YZ, et al. Dihydromyricetin inhibits cell proliferation, migration, invasion and promotes apoptosis via regulating miR-21 in human cholangiocarcinoma cells[J]. J Cancer, 2020, 11(19): 5689-5699. DOI: 10.7150/jca.45970.
    [10]
    LIU H, WANG J, TAO Y, et al. Curcumol inhibits colorectal cancer proliferation by targeting miR-21 and modulated PTEN/PI3K/Akt pathways[J]. Life Sci, 2019, 221: 354-361. DOI: 10.1016/j.lfs.2019.02.049.
    [11]
    SCHMITTGEN TD, LIVAK KJ. Analyzing real-time PCR data by the comparative C(T) method[J]. Nat Protoc, 2008, 3(6): 1101-1108. DOI: 10.1038/nprot.2008.73.
    [12]
    MCGEARY SE, LIN KS, SHI CY, et al. The biochemical basis of microRNA targeting efficacy[J]. Science, 2019, 366(6472): eaav1741. DOI: 10.1126/science.aav1741.
    [13]
    ZOU Y, LI R, KUANG D, et al. Galangin inhibits cholangiocarcinoma cell growth and metastasis through downregulation of MicroRNA-21 expression[J]. Biomed Res Int, 2020, 2020: 5846938. DOI: 10.1155/2020/5846938.
    [14]
    NARAYANAN S, CAI CY, ASSARAF YG, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance[J]. Drug Resist Updat, 2020, 48: 100663. DOI: 10.1016/j.drup.2019.100663.
    [15]
    MOLLAEI H, SAFARALIZADEH R, ROSTAMI Z. MicroRNA replacement therapy in cancer[J]. J Cell Physiol, 2019, 234(8): 12369-12384. DOI: 10.1002/jcp.28058.
    [16]
    SALIMINEJAD K, KHORRAM KHORSHID HR, SOLEYMANI FARD S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods[J]. J Cell Physiol, 2019, 234(5): 5451-5465. DOI: 10.1002/jcp.27486.
    [17]
    ROSSI M, ALTOMARE E, BOTTA C, et al. miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma[J]. Leukemia, 2021, 35(3): 823-834. DOI: 10.1038/s41375-020-0947-1.
    [18]
    WANG H, TAN Z, HU H, et al. microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1[J]. BMC Cancer, 2019, 19(1): 738. DOI: 10.1186/s12885-019-5951-3.
    [19]
    WANG B, HUA P, ZHANG L, et al. LncRNA-IUR up-regulates PTEN by sponging miR-21 to regulate cancer cell proliferation and apoptosis in esophageal squamous cell carcinoma[J]. Esophagus, 2020, 17(3): 298-304. DOI: 10.1007/s10388-020-00724-x.
    [20]
    TAN AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)[J]. Thorac Cancer, 2020, 11(3): 511-518. DOI: 10.1111/1759-7714.13328.
    [21]
    JANG DK, LEE YG, CHAN CHAE Y, et al. GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway[J]. Biochem Biophys Res Commun, 2020, 529(4): 1242-1248. DOI: 10.1016/j.bbrc.2020.06.011.
    [22]
    ZHANG XM, LIU ZL, QIU B, et al. Downregulation of EVI1 expression inhibits cell proliferation and induces apoptosis in hilar cholangiocarcinoma via the PTEN/AKT signalling pathway[J]. J Cancer, 2020, 11(6): 1412-1423. DOI: 10.7150/jca.31903.
    [23]
    LI G, ZHANG C, LIANG W, et al. Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts synergistically with 17-AAG and SAHA in SW480 colon cancer cells[J]. Pharm Biol, 2021, 59(1): 21-30. DOI: 10.1080/13880209.2020.1865407.
    [24]
    LIU HY, ZHANG YY, ZHU BL, et al. miR-21 regulates the proliferation and apoptosis of ovarian cancer cells through PTEN/PI3K/AKT[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10): 4149-4155. DOI: 10.26355/eurrev_201905_17917.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(9)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (479) PDF downloads(30) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return